Alzamend Neuro Proxy Statement Filed for April 25 Meeting
Ticker: ALZN · Form: DEF 14A · Filed: Mar 13, 2025 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | DEF 14A |
| Filed Date | Mar 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
TL;DR
Alzamend Neuro proxy filed - shareholders vote on exec pay & board April 25.
AI Summary
Alzamend Neuro, Inc. filed its definitive proxy statement on March 13, 2025, for its annual meeting on April 25, 2025. The company, focused on treatments for Alzheimer's disease, is seeking shareholder approval for various corporate matters. The filing details executive compensation, board nominations, and other proposals requiring shareholder votes.
Why It Matters
This filing outlines key decisions shareholders will vote on, including executive compensation and board composition, which can impact the company's strategic direction and future performance.
Risk Assessment
Risk Level: medium — Proxy statements often involve proposals that can significantly alter corporate governance or financial structures, carrying inherent risks for investors.
Key Numbers
- 20250313 — Filing Date (The date the proxy statement was filed with the SEC.)
- 20250425 — Meeting Date (The date of the shareholder meeting where votes will be cast.)
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- March 13, 2025 (date) — Filing Date
- April 25, 2025 (date) — Meeting Date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information and solicit their votes for the annual meeting scheduled for April 25, 2025, covering matters such as director elections and executive compensation.
Who is the filer of this proxy statement?
The filer is Alzamend Neuro, Inc., as indicated by the 'Registrant' status.
When was this proxy statement filed with the SEC?
This proxy statement was filed with the SEC on March 13, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on April 30.
What is the company's primary business sector?
The company operates in the Pharmaceutical Preparations sector, SIC code 2834.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 13, 2025 regarding Alzamend Neuro, Inc. (ALZN).